Greenstone LLC
3 drugs in NADAC|3 Generic,0 Brand
View Recalls (7)Greenstone LLC lists 3 NDCs in the CMS NADAC file (3 generic, 0 brand), at an average NADAC of $0.91 per unit, with a week-over-week move of -3.3% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.
Total Drugs
3
3G / 0B
Avg Price / Unit
$0.9055
$0.18 – $2.35
Avg 7d Change
-3.32%
Across 3 drugs with changes
7d Activity
of 3 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Frequently Asked Questions
How many drugs does Greenstone LLC make?
Greenstone LLC lists 3 NDCs in the CMS NADAC file — 3 generic and 0 brand products.
What is the average price of Greenstone LLC drugs?
The average NADAC across Greenstone LLC's portfolio is $0.9055 per unit, ranging from $0.1830 to $2.3505.
What types of drugs does Greenstone LLC make?
Greenstone LLC makes drugs across 2 FDA pharmacologic classes. The most common by NDC count are Aluminum Complex (2), Aminosalicylate (1).
Has Greenstone LLC had any drug recalls?
7 FDA recalls are matched to Greenstone LLC in the openFDA feed, most recently on Jan 15, 2026.
How has Greenstone LLC's pricing changed recently?
Over the past 7 days, 0 Greenstone LLC products rose and 3 fell, with a portfolio-wide average change of -3.3%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
MESALAMINE DR 400 MG CAPSULE MESALAMINE | $2.3504 per EA | -2.29% |
SUCRALFATE 1 GM TABLET Sucralfate | $0.1830 per EA | -3.83% |
SUCRALFATE 1 GM TABLET Sucralfate | $0.1830 per EA | -3.83% |
FDA Recalls (7)
Recalls matched by company name. Verify current status with FDA.
methylprednisolone tablets, USP Dosepak, 4 mg, 1 Blister Card per Carton containing 21 Tablets, Rx only, Distributed by: Greenstone LLC, Peapack, NJ 07977. NDC 59762-4440-2
Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.
Venlafaxine HCl Extended-Release Capsules, 150 mg, 90-count Unit of Use bottles, Rx only, Distributed by: Greenstone LLC, Peapack, NJ 07977, NDC 59762-0182-2, UPC 3 59762-0182-2 9.
Presence of Foreign Tablets/Capsules: report of a foreign capsule with markings (TKN 250) and identified as a Tikosyn (dofetilide) capsule was found in a bottle of Effexor XR (venlafaxine HCl) 150 mg capsules that was packaged in the same packaging campaign as the recalled lot
sertraline HCl tablets, 25 mg, 30 Tablets, Rx only, GREENSTONE BRAND --- Distributed by: Greenstone LLC, Peapack, NJ 07977 -- MADE IN INDIA --- NDC 59762-4960-1
Labeling: Incorrect or Missing Lot No. and/or Exp Date: Expiration date incorrectly reflects a 36 month shelf life, instead of the 24 month shelf life
Glipizide XL (glipizide) extended release tablets, 5 mg , 500 count bottles, Rx only, Distributed by: Greenstone Ltd., Peapack, NJ --- NDC 59762-5032-2
Failed Dissolution Specification; the bulk lot yielded an out of specification result at the 8 hr timepoint, 18 month interval
Nifedipine, extended-release tablets, 90mg 100 count blister pack, Rx only, Distributed by: GREENSTONE LLC, Pespack, NJ,07977, NDC 59762-6692-8
Labeling: Incorrect or Missing Lot and/or Exp Date: Greenstone LLC is recalling Nifedipine Extended Release tablets (90mg). The expiration date on the package is 48 months instead of 36 months.
Spironolactone tablets, USP 25 mg, Rx only, 500 count bottle, Distributed By: Greenstone LLC, Peapack, NJ 07977, NDC: 59762-5011-2.
Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved application supporting the alternate manufacturing site.
Spironolactone tablets, USP 50 mg, Rx only, 100 count bottle, Distributed By: Greenstone LLC, Peapack, NJ 07977, NDC: 59762-5012-1
Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved application supporting the alternate manufacturing site.